Core Insights - AkzoNobel reported stable organic sales in Q2 2025 compared to Q2 2024, with a 2% increase in pricing but a 6% decline in sales due to adverse currency effects [1] - Adjusted EBITDA for Q2 2025 was €393 million, including a €24 million negative currency impact, compared to €400 million in 2024 [1] - The adjusted EBITDA margin improved to 15.0%, an increase of 60 basis points from 2024 [1] - Cash generated from operating activities was €234 million, significantly higher than €151 million in the same period of 2024 [1] Financial Performance - For the first half of 2025, organic sales remained flat, with a 3% decline in sales due to adverse currency effects [1] - Adjusted EBITDA for H1 2025 was €750 million, including a €31 million negative currency impact, compared to €763 million in 2024 [1] - The adjusted EBITDA margin for H1 2025 was 14.3% [1] - Cash generated from operating activities for H1 2025 was €122 million, reversing the negative €19 million from the same period in 2024 [1] Strategic Developments - CEO Greg Poux-Guillaume highlighted improved profitability in Q2 due to strict pricing strategies and operational efficiency initiatives [2] - The company is facing significant currency pressure from a strong euro and weak overall market demand but has demonstrated strong business performance [2] - AkzoNobel has signed a binding agreement to sell its Indian subsidiary to JSW Group, marking a significant step in its portfolio strategy assessment [2] - The transaction is expected to be completed in Q4 2025 [2]